专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20170168071A1 P-SELECTIN ASSOCIATED WITH EOSINOPHILS AS A MARKER FOR ASTHMA AND CORRELATING WITH B-1 INTEGRIN ACTIVATION 审中-公开
公开(公告)号：US20170168071A1
公开(公告)日：2017-06-15
申请号：US15443544
申请日：2017-02-27
申请人： Wisconsin Alumni Research Foundation
发明人： Mats W. Johansson , Deane F. Mosher
IPC分类号： G01N33/68 , G01N33/569
CPC分类号： G01N33/6893 , G01N33/566 , G01N33/56972 , G01N33/6884 , G01N2333/70564 , G01N2800/122
摘要： Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition.

82. 发明申请

US20160231338A1 Method of Detection of Platelet-Activating Antibodies That Cause Heparin-Induced Thrombocytopenia/Thrombosis 有权
标题翻译：检测引起肝素诱导的血小板减少/血栓形成的血小板活化抗体的方法
公开(公告)号：US20160231338A1
公开(公告)日：2016-08-11
申请号：US14437066
申请日：2014-10-28
申请人： BLOODCENTER RESEARCH FOUNDATION
发明人： Richard H. ASTER , Daniel W. BOUGIE , Curtis Gerald JONES , Anand PADMANABHAN
IPC分类号： G01N33/86 , G01N33/569 , G01N33/68
CPC分类号： G01N33/86 , C12Q1/56 , G01N33/56966 , G01N33/6854 , G01N2333/70564 , G01N2800/222 , G01N2800/224 , G01N2800/226
摘要： The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombo-cytopenia (HIT); b) incubating an effective amount of platelet factor 4 (PF4) with a sample of platelets to yield a sample of PF4-treated platelets; c) contacting the patient blood sample with the PF4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having HIT.
摘要翻译：本发明提供一种检测患者血小板活化的方法，所述方法包括以下步骤：a）从疑似肝素诱导的血小板减少症（HIT）的患者获得血液样品; b）将有效量的血小板因子4（PF4）与血小板样品一起孵育，得到经PF4处理的血小板样品; c）将患者血液样品与PF4处理的血小板接触; 和d）测量血小板活化的程度，其中与使用正常血液样品获得的结果相比，血小板活化的增加指示患有HIT的患者。

83. 发明申请

US20150105278A1 METHODS OR RISK ASSESSMENT OF PML AND RELATED APPARATUS 审中-公开
标题翻译： PML及相关装置的方法或风险评估
公开(公告)号：US20150105278A1
公开(公告)日：2015-04-16
申请号：US14352402
申请日：2012-10-16
申请人： WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
发明人： Nicholas Schwab , Tilman Schneider-Hohendorf , Heinz Wiendl
IPC分类号： G01N33/68 , C12Q1/68
CPC分类号： G01N33/6872 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , G01N33/56972 , G01N33/6893 , G01N33/6896 , G01N2333/70553 , G01N2333/70564 , G01N2800/28 , G01N2800/50 , G01N2800/52
摘要： The invention provides a method of assessing the risk of occurrence of progressive multifocal leukoencephalopathy (PML) in a subject as well as a method of stratifying a subject undergoing VLA-4 blocking agent treatment for suspension of VLA-4 blocking agent treatment. These methods comprise detecting the level of L-selectin (CD62L) and optionally LFA-1 expressing T cells in a sample from the subject.
摘要翻译：本发明提供一种评估受试者中进行性多灶性脑白质病（PML）发生风险的方法以及对VLA-4阻断剂治疗VLA-4阻断剂治疗悬浮液进行VLA-4封闭剂治疗的受试者分层方法。这些方法包括检测来自受试者的样品中L-选择蛋白（CD62L）和任选的LFA-1表达T细胞的水平。

84. 发明授权

US07807636B1 Bovine P-selectin glycorpotein ligand-1 失效
标题翻译：牛P-选择蛋白glycorpotein配体-1
公开(公告)号：US07807636B1
公开(公告)日：2010-10-05
申请号：US11512934
申请日：2006-08-30
申请人： Benjamin J. Darien
发明人： Benjamin J. Darien
IPC分类号： A61K38/00 , A61K38/16 , C12P21/06 , C07K14/00 , C07K16/00
CPC分类号： G01N33/6893 , C07K14/47 , G01N2333/70564
摘要： A novel bovine P-selectin glycoprotein ligand-1 (bPSGL-1) is disclosed having the amino acid sequence set forth in SEQ. ID. NO:1. DNA sequences encoding the bPSGL-1 are also disclosed, along with vectors, host cells, and methods of using the bPSGL-1. The invention further provides methods for preventing or reducing acute inflammatory response in a bovine subject by administering bPSGL-1 and fragments thereof (e.g., a bPSGL-1 Ig fusion protein). The invention also provides methods for identifying compounds of reducing or preventing damage to tissue or organs caused by acute inflammatory response in a bovine.
摘要翻译：公开了一种新型牛P-选择蛋白糖蛋白配体-1（bPSGL-1），其具有SEQ ID NO：1所示的氨基酸序列。 ID。 NO：1。还公开了编码bPSGL-1的DNA序列，以及载体，宿主细胞和使用bPSGL-1的方法。本发明还提供了通过施用bPSGL-1及其片段（例如，bPSGL-1 Ig融合蛋白）来预防或减少牛对象中急性炎症反应的方法。本发明还提供了用于鉴定减少或预防由牛中的急性炎症反应引起的对组织或器官的损伤的化合物的方法。

85. 发明申请

US20100104502A1 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ENDOTHELIAL DYSFUNCTION 审中-公开
标题翻译：用于检测和治疗内皮功能障碍的组合物和方法
公开(公告)号：US20100104502A1
公开(公告)日：2010-04-29
申请号：US12513826
申请日：2007-11-06
申请人： Daniel T. Eitzman , Peter F. Bodary , Jonaton W. Homeister
发明人： Daniel T. Eitzman , Peter F. Bodary , Jonaton W. Homeister
IPC分类号： G01N33/53 , A61K51/00 , A61K49/00 , A61K49/06 , A61K49/04 , C12Q1/68
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2333/70503 , G01N2333/70525 , G01N2333/70564 , G01N2800/32 , G01N2800/52
摘要： The present invention relates to endothelial dysfunction. In particular, the present invention provides biomarkers of endothelial dysfunction (e.g., vascular disease), and compositions and methods of using the same. Compositions and methods of the present invention find use in, among other things, research, clinical, diagnostic, drug discovery, and therapeutic applications.
摘要翻译：本发明涉及内皮功能障碍。特别地，本发明提供内皮功能障碍（例如血管疾病）的生物标志物，以及使用其的组合物和方法。本发明的组合物和方法尤其可用于研究，临床，诊断，药物发现和治疗应用。

86. 发明申请

US20100081630A1 Heparin Compositions and Selectin Inhibition 审中-公开
标题翻译：肝素组合物和选择素抑制
公开(公告)号：US20100081630A1
公开(公告)日：2010-04-01
申请号：US12630106
申请日：2009-12-03
申请人： Ajit Varki , Jennifer L. Stevenson
发明人： Ajit Varki , Jennifer L. Stevenson
IPC分类号： A61K31/727 , C12Q1/48
CPC分类号： G01N33/566 , A61K31/727 , G01N33/66 , G01N33/86 , G01N2333/70564 , G01N2400/40 , G01N2500/02 , G01N2500/10 , G01N2800/224 , A61K2300/00
摘要： The disclosure provides in vitro and in vivo methods for identifying Heparins and Heparinoids that modulate the activity of selectins. The disclosure also provides Heparins and Heparinoids that modulate the activity of selectins. The identification and isolation of these heparin formulations has the potential to mediate a wide variety of pathologies mediated by P- and/or L-selectin, including hematogenous metastasis, diseases associated with inflammation (e.g., asthma, arthritis, allergic dermatitis), ischemia-reperfusion injury, or other pathologies such as sickle cell anemia. Selectin inhibition can be achieved at plasma concentrations lower than those that cause excessive anticoagulation or unwanted bleeding in a human subject.
摘要翻译：本公开提供用于鉴定调节选择素活性的肝素和类肝素的体外和体内方法。本公开还提供调节选择素活性的肝素和类肝素。这些肝素制剂的鉴定和分离具有介导由P-和/或L-选择蛋白介导的多种病理学的潜力，包括血液转移，与炎症相关的疾病（例如哮喘，关节炎，过敏性皮炎），缺血 - 再灌注损伤或其他病态如镰状细胞性贫血。选择素抑制可以在血浆浓度低于在人类受试者中引起过度抗凝或不想要的出血的浓度下实现。

87. 发明申请

US20080193949A1 METHODS FOR DIAGNOSING AND TREATING HEMOSTATIC DISORDERS BY MODULATING P-SELECTIN ACTIVITY 审中-公开
标题翻译：通过调节P-选择素活性来诊断和治疗嗜酸粒细胞性疾病的方法
公开(公告)号：US20080193949A1
公开(公告)日：2008-08-14
申请号：US12030576
申请日：2008-02-13
申请人： Denisa D. Wagner , Patrick Andre , Daqing W. Hartwell , Ingrid Hrachovinova
发明人： Denisa D. Wagner , Patrick Andre , Daqing W. Hartwell , Ingrid Hrachovinova
IPC分类号： G01N33/566
CPC分类号： G01N33/86 , A61K38/178 , A61K48/00 , C07K2319/30 , G01N2333/70564
摘要： The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of a hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.
摘要翻译：本发明鉴定了P-选择蛋白作为止血调节剂。因此，本发明涉及用于鉴定和使用P-选择蛋白活性的调节剂作为止血调节剂的方法。本发明还涉及用于诊断和治疗止血障碍的方法和组合物，包括但不限于出血性疾病和血栓形成障碍。本发明描述了用于各种止血条件的诊断评估和预后的方法，以及用于鉴定表现出对这些病症倾向的受试者。此外，本发明提供了用于诊断监测临床评估用于治疗止血或血管疾病以及用于监测化合物在临床试验中的功效的患者的诊断监测方法。

88. 发明授权

US07175990B2 Method of determining endometrial receptivity 失效
标题翻译：确定子宫内膜容受性的方法
公开(公告)号：US07175990B2
公开(公告)日：2007-02-13
申请号：US10374318
申请日：2003-02-25
申请人： Susan J. Fisher , Olga Genbacev-Krtolica , Akraporn Prakobphol , Michael T. McMaster
发明人： Susan J. Fisher , Olga Genbacev-Krtolica , Akraporn Prakobphol , Michael T. McMaster
IPC分类号： G01N33/53
CPC分类号： G01N33/689 , A61K2039/505 , C07K16/2854 , G01N2333/70564 , G01N2800/368
摘要： The present invention provides a method of predicting the probability of a successful pregnancy, either a naturally achieved pregnancy or a pregnancy resulting from an assisted reproductive technology, based on the level of L-selectin ligand expressed by uterine epithelial cells and/or the level of L-selectin expressed by an embryo in vitro. The invention further provides methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell. Methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell are useful to inhibit pregnancy. The invention further provides methods of assessing in vitro embryo quality. The invention further provides methods of predicting the probability of continued success of a pregnancy during the first 16 weeks of gestation.
摘要翻译：本发明提供了一种基于由子宫上皮细胞表达的L-选择蛋白配体的水平和/或水平的预测基于辅助生殖技术产生的天然获得的怀孕或妊娠成功怀孕的概率的方法体外由胚胎表达的L-选择蛋白。本发明还提供了抑制滋养层与子宫上皮细胞之间的细胞粘附的方法。抑制滋养层和子宫上皮细胞之间的细胞粘附的方法可用于抑制怀孕。本发明还提供了评估体外胚胎质量的方法。本发明还提供了预测妊娠前16周怀孕继续成功的可能性的方法。

89. 发明申请

US20050202007A1 Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity 审中-公开
标题翻译：通过调节P-选择蛋白活性来诊断和治疗止血障碍的方法
公开(公告)号：US20050202007A1
公开(公告)日：2005-09-15
申请号：US10999477
申请日：2004-11-30
申请人： Denisa Wagner , Patrick Andre , Daqing Hartwell , Ingrid Hrachovinova
发明人： Denisa Wagner , Patrick Andre , Daqing Hartwell , Ingrid Hrachovinova
IPC分类号： A61K45/00 , A61K38/00 , A61K38/17 , A61K39/395 , A61K48/00 , A61P7/00 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/10 , A61P35/00 , A61P43/00 , G01N33/86
CPC分类号： G01N33/86 , A61K38/178 , A61K48/00 , C07K2319/30 , G01N2333/70564
摘要： The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of a hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.
摘要翻译：本发明鉴定了P-选择蛋白作为止血调节剂。因此，本发明涉及用于鉴定和使用P-选择蛋白活性的调节剂作为止血调节剂的方法。本发明还涉及用于诊断和治疗止血障碍的方法和组合物，包括但不限于出血性疾病和血栓形成障碍。本发明描述了用于各种止血条件的诊断评估和预后的方法，以及用于鉴定表现出对这些病症倾向的受试者。此外，本发明提供了用于诊断监测临床评估用于治疗止血或血管疾病以及用于监测化合物在临床试验中的功效的患者的诊断监测方法。

90. 发明申请

US20040096396A1 Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis 审中-公开
标题翻译：用于诊断和治疗涉及血管生成的医学病症的组合物和方法
公开(公告)号：US20040096396A1
公开(公告)日：2004-05-20
申请号：US10601080
申请日：2003-06-19
申请人： GlycoMimetics, Inc.
发明人： John L. Magnani , John T. Patton JR.
IPC分类号： A61K049/00
CPC分类号： A61K49/0004 , G01N2333/70564 , G01N2500/10
摘要： Compositions and methods are provided for diagnosis or therapy of medical conditions, or for tissue engineering, involving angiogenesis accompanied by the expression of E-selectin. More specifically, compounds are used that are selective for E-selectin binding with no significant ability to bind to P-selectin.
摘要翻译：提供用于诊断或治疗医学病症或组织工程的组合物和方法，其涉及伴随E-选择素表达的血管生成。更具体地，使用对E-选择蛋白结合具有选择性的化合物，其不具有结合P-选择蛋白的显着能力。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式